PLK1 and its role in the evolving landscape of KRAS-mutated colorectal cancer

被引：1
|
作者：
Harvey, Harry [1 ]
Chen, Eric Xueyu [1 ]
机构：
[1] Univ Toronto, Univ Hlth Network, Princess Margaret Canc Ctr, 7-824,700 Univ Ave, Toronto, ON M5G 1Z5, Canada
来源：
JOURNAL OF GASTROINTESTINAL ONCOLOGY | 2024年 / 15卷 / 04期
关键词：
Kirsten rat sarcoma virus (KRAS); colorectal cancer (CRC); targeted therapy; RAS; INHIBITOR; FOLFIRI; BEVACIZUMAB; GEMCITABINE; COMBINATION; ISIS-2503;
D O I：
10.21037/jgo-24-323
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：1987 / 1992
页数：6
相关论文
共 50 条
  • [31] Non-engineered T cells with specific anticancer effects in KRAS-mutated colorectal cancer
    Lim, Sunki
    Gho, Yujeong
    Kim, Seoyoung
    Kim, Min Ki
    Park, Jong Seob
    Lee, Wang Jun
    Lee, Young-Kwan
    Moon, Hyoun Jong
    CANCER RESEARCH, 2023, 83 (07)
  • [32] KRAS-mutated plasma DNA as predictor of outcome from irinotecan monotherapy in metastatic colorectal cancer
    K G Spindler
    A L Appelt
    N Pallisgaard
    R F Andersen
    A Jakobsen
    British Journal of Cancer, 2013, 109 : 3067 - 3072
  • [33] MicroRNA Expression Signatures Associated With BRAF-Mutated Versus KRAS-Mutated Colorectal Cancers
    Choi, Yong Won
    Song, Young Soo
    Lee, Hyunwoo
    Yi, Kijong
    Kim, Young-Bae
    Suh, Kwang Wook
    Lee, Dakeun
    MEDICINE, 2016, 95 (15)
  • [34] Clinical Response to T-DM1 in HER2-Amplified, KRAS-Mutated Metastatic Colorectal Cancer
    Sandhu, Jaideep
    Wang, Chongkai
    Fakih, Marwan
    JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK, 2020, 18 (02): : 116 - 119
  • [35] Potential treatment target discovered for KRAS-mutated colon cancer
    不详
    COLORECTAL CANCER, 2012, 1 (02) : 100 - 100
  • [36] THE ROLE OF ASPARAGINE SYNTHETASE IN COLORECTAL CANCER WITH MUTATED KRAS.
    Toda, K.
    Kawada, K.
    Iwamoto, M.
    Inamoto, S.
    Hasegawa, S.
    Sakai, Y.
    DISEASES OF THE COLON & RECTUM, 2017, 60 (06) : E117 - E118
  • [37] DECIPHERING THE ROLE OF PARP-1 AS A THERAPEUTIC TARGET IN KRAS-MUTATED INTRAHEPATIC CHOLANGIOCARCINOMA
    Mahn, Friederike L.
    Castven, Darko
    Pereira, Sharon P.
    Hartmann, Monika
    Fahrer, Jorg
    Oliveira, Douglas V.
    Andersen, Jesper B.
    Matter, Matthias
    Roessler, Stephanie
    Kaina, Bernd
    Galle, Peter R.
    Marquardt, Jens U.
    HEPATOLOGY, 2019, 70 : 1143A - 1143A
  • [38] Comment on 'KRAS-mutated plasma DNA as predictor of outcome from irinotecan monotherapy in metastatic colorectal cancer'
    Tougeron, D.
    Laurent-Puig, P.
    Zaanan, A.
    BRITISH JOURNAL OF CANCER, 2014, 111 (12) : 2379 - 2380
  • [39] Comment on ‘KRAS-mutated plasma DNA as predictor of outcome from irinotecan monotherapy in metastatic colorectal cancer’
    D Tougeron
    P Laurent-Puig
    A Zaanan
    British Journal of Cancer, 2014, 111 : 2379 - 2380
  • [40] Expanded access program of the PLK1 inhibitor onvansertib for treatment of patients with KRAS-mutant metastatic colorectal cancer.
    Sharma, Manish R.
    Isaac, Daniel
    Ramaekers, Ryan
    Ridinger, Maya
    Erlander, Mark
    Mendelsohn, Lawrence
    CANCER RESEARCH, 2021, 81 (13)
12345